Revlimid 5 mg Capsules Special Use-results Surveillance of Long Term Use
Latest Information Update: 16 Jun 2022
Price :
$35 *
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 13 Jun 2022 Status changed from active, no longer recruiting to completed.
- 21 May 2020 Planned End Date changed from 31 Dec 2019 to 19 Jun 2020.
- 21 May 2020 Planned primary completion date changed from 31 Dec 2019 to 19 Jun 2020.